Patterns of immune recovery after axicabtagene ciloleucel for aggressive B-cell lymphoma.

ABSTRACT: Hematotoxicity after anti-CD19 chimeric antigen receptor T-cell therapy has drawn attention for potential long-term effects, and yet, recovery of lymphocyte subsets and immunoglobulin levels beyond B-cell aplasia remains poorly understood. We retrospectively analyzed 76 consecutive axicabtagene ciloleucel (axi-cel) recipients with relapsed/refractory aggressive B-cell lymphoma between 2020 and 2024, focusing on basic immune recovery patterns and their impact on outcomes. Median CD8⁺ T and NK cells increased to >300/mm³ and >100/mm³, respectively, within 2 months after infusion. CD4⁺ T-cell recovery was slower, with 42% cumulative incidence of >200/mm³ cell count at 12 months. B-cells were detectable in 18% at 12 months. Immunoglobulin

SUBMITTER: Airosa Pardal A 

PROVIDER: S-EPMC12497443 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature